{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:19:39Z","timestamp":1791231579339,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.autrev.2025.103956","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:13:22Z","timestamp":1761783202000},"page":"103956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Are the 2023 ACR\/EULAR classification criteria a step forward in the management of antiphospholipid syndrome? A literature-based and clinical practice appraisal"],"prefix":"10.1016","volume":"25","author":[{"given":"Jaume","family":"Alijotas-Reig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Marques-Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Esteve-Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Anunciaci\u00f3n-Llunell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Andrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ockova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariella","family":"Hoxha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munther A.","family":"Khamashta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Mir\u00f3-Mur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103956_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2019.101463","article-title":"Antiphospholipid syndrome","volume":"34","author":"Sammaritano","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103956_bb0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.trsl.2020.04.006","article-title":"Antiphospholipid syndrome","volume":"225","author":"Petri","year":"2020","journal-title":"Transl Res"},{"key":"10.1016\/j.autrev.2025.103956_bb0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/OGX.0b013e3181c97809","article-title":"Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?","volume":"65","author":"Alijotas-Reig","year":"2010","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.autrev.2025.103956_bb0020","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.40901","article-title":"The epidemiology of antiphospholipid syndrome: a population-based study","volume":"71","author":"Duarte-Garc\u00eda","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103956_bb0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"Dabit","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2025.103956_bb0030","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/acr.22583","article-title":"Distinctions between diagnostic and classification criteria?","volume":"67","author":"Aggarwal","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103956_bb0035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103956_bb0040","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR \/ EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103956_bb0045","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103956_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(25)00094-3","article-title":"Towards precision medicine in antiphospholipid syndrome","author":"Lopez-Pedrera","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103956_bb0055","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S2665-9913(24)00396-5","article-title":"Diagnostic, research, and real-life effect of the 2023 EULAR\u2212ACR classification criteria for antiphospholipid syndrome","volume":"7","author":"Schreiber","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103956_bb0060","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/art.42792","article-title":"Correspondence and comments on American College of Rheumatology and EULAR antiphospholipid syndrome classification criteria: comment on the article by Barbhaiya et al","volume":"76","author":"Alijotas-Reig","year":"2024","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103956_bb0065","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.jtha.2024.03.027","article-title":"Dilemmas in the diagnosis and management of antiphospholipid syndrome","volume":"22","author":"Manning","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103956_bb0070","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2025.103956_bb0075","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103956_bb0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/BOR.0000000000000932","article-title":"Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach","volume":"35","author":"Ambati","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103956_bb0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/BOR.0000000000000702","article-title":"Treatment of thrombotic antiphospholipid syndrome in adults and children","volume":"32","author":"Madison","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103956_bb0090","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.thromres.2013.04.012","article-title":"Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study","volume":"132","author":"Zuily","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2025.103956_bb0095","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/rheumatology\/kex466","article-title":"Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis","volume":"57","author":"Sciascia","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103956_bb0100","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood.2023020727","article-title":"How I diagnose and treat antiphospholipid syndrome in pregnancy","volume":"143","author":"Branch","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103956_bb0105","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1001\/jama.2025.2033","article-title":"Long-term risk of stroke after transient ischemic attack or minor stroke: a systematic review and meta-analysis","volume":"333","author":"Khan","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2025.103956_bb0110","first-page":"54","article-title":"Diagnosis, workup, risk reduction of transient ischemic attack in the emergency department setting: a scientific statement from the American Heart Association","author":"Amin","year":"2023","journal-title":"Stroke"},{"key":"10.1016\/j.autrev.2025.103956_bb0115","first-page":"499","article-title":"Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome","volume":"23","author":"Toubi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103956_bb0120","series-title":"Skin problems related to antiphospholipid syndrome | HSS","year":"2025"},{"key":"10.1016\/j.autrev.2025.103956_bb0125","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/2229-5178.164493","article-title":"Livedo reticularis: a review of the literature","volume":"6","author":"Sajjan","year":"2015","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.autrev.2025.103956_bb0130","first-page":"2379","article-title":"Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome","volume":"33","author":"Uthman","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103956_bb0135","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae302","article-title":"Anti-phospholipid antibodies nephropathy is associated with an increased risk of kidney failure: a systematic literature review and meta-analysis","volume":"17","author":"Hoxha","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.autrev.2025.103956_bb0145","author":"Management of Stillbirth"},{"key":"10.1016\/j.autrev.2025.103956_bb0150","series-title":"Definitions of terms used in the MBRRACE-UK Perinatal Mortality Surveillance Report","author":"MBRRACE-UK","year":"2015"},{"key":"10.1016\/j.autrev.2025.103956_bb0155","author":"Early Pregnancy Loss"},{"key":"10.1016\/j.autrev.2025.103956_bb0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/humrep\/deu299","article-title":"Terminology for pregnancy loss prior to viability: a consensus statement from the ESHRE early pregnancy special interest group","volume":"30","author":"Kolte","year":"2015","journal-title":"Hum Reprod"},{"key":"10.1016\/j.autrev.2025.103956_bb0170","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2174\/1389201019666180712115215","article-title":"HELLP syndrome: pathophysiology and current therapies","volume":"19","author":"Wallace","year":"2018","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.autrev.2025.103956_bb0175","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0961203311425520","article-title":"Prevalence and clinical usefulness of antiphospholipid and anticofactor antibodies in different Spanish preeclampsia subsets","volume":"21","author":"Ferrer-Oliveras","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2025.103956_bb0180","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.autrev.2014.12.010","article-title":"The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases","volume":"14","author":"Alijotas-Reig","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103956_bb0185","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3390\/biomedicines11082298","article-title":"Preeclampsia and the antiphospholipid syndrome","volume":"11","author":"Mayer-Pickel","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2025.103956_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103101","article-title":"Antiphospholipid antibodies in women with recurrent embryo implantation failure: a systematic review and meta-analysis","volume":"21","author":"Jarne-Borr\u00e0s","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103956_bb0195","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/jcm11030675","article-title":"Pathogenesis, diagnosis and management of obstetric antiphospholipid syndrome: a comprehensive review","volume":"11","author":"Alijotas-Reig","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2025.103956_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13312","article-title":"Antiphospholipid antibodies and extracellular vesicles in pregnancy","volume":"85","author":"Tong","year":"2021","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.autrev.2025.103956_bb0205","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3390\/biomedicines11102681","article-title":"Trophoblast cell function in the antiphospholipid syndrome","volume":"11","author":"Vrzi\u0107 Petronijevi\u0107","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2025.103956_bb0210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0039-1697982","article-title":"Antiphospholipid antibody syndrome and infertility","volume":"41","author":"Rodrigues","year":"2019","journal-title":"Rev Bras Ginecol E Obstetr\u00edcia RBGO Gynecol Obstet"},{"key":"10.1016\/j.autrev.2025.103956_bb0215","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/art.40416","article-title":"Antiphospholipid antibodies inhibit trophoblast toll-like receptor and inflammasome negative regulators","volume":"70","author":"Mulla","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103956_bb0220","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/1529-0131(200001)43:1<140::AID-ANR18>3.0.CO;2-P","article-title":"Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered \u03b22-glycoprotein I","volume":"43","author":"Di Simone","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103956_bb0225","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103956_bb0230","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.amjcard.2005.04.022","article-title":"Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome","volume":"96","author":"Turiel","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.autrev.2025.103956_bb0235","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11926-013-0320-8","article-title":"Valvular heart disease in antiphospholipid syndrome","volume":"15","author":"Zuily","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2025.103956_bb0240","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/rheumatology\/keab475","article-title":"Persistent thrombocytopenia predicts poor long-term survival in patients with antiphospholipid syndrome: a 38-year follow-up study","volume":"61","author":"Pardos-Gea","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103956_bb0245","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.medcli.2016.11.026","article-title":"Trombocitopenia como factor de riesgo tromb\u00f3tico en pacientes con anticuerpos antifosfolip\u00eddicos sin criterios de enfermedad","volume":"148","author":"Demetrio Pablo","year":"2017","journal-title":"Med Cl\u00edn"},{"key":"10.1016\/j.autrev.2025.103956_bb0250","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/jth.13763","article-title":"Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study","volume":"15","author":"Hisada","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103956_bb0255","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1097\/AOG.0000000000003100","article-title":"207: thrombocytopenia in pregnancy","volume":"133","author":"ACOG Practice Bulletin No","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.autrev.2025.103956_bb0260","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1055\/s-0040-1721350","article-title":"Update on thrombocytopenia in pregnancy","volume":"42","author":"Subtil","year":"2020","journal-title":"Rev Bras Ginecol E Obstetr\u00edcia RBGO Gynecol Obstet"},{"key":"10.1016\/j.autrev.2025.103956_bb0265","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1576\/toag.11.3.177.27502","article-title":"Thrombocytopenia in pregnancy","volume":"11","author":"Myers","year":"2009","journal-title":"Obstet Gynaecol"},{"key":"10.1016\/j.autrev.2025.103956_bb0270","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/09537104.2019.1640870","article-title":"Managing ITP and thrombocytopenia in pregnancy","volume":"31","author":"Eslick","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.autrev.2025.103956_bb0275","first-page":"55","article-title":"Thrombocytopenia in Pregnancy","volume":"11","author":"Ciobanu","year":"2016","journal-title":"Maedica"},{"key":"10.1016\/j.autrev.2025.103956_bb0280","series-title":"2013 clinical practice guide on thrombocytopenia in pregnancy","author":"Rajasekhar","year":"2006"},{"key":"10.1016\/j.autrev.2025.103956_bb0285","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1802897","article-title":"Platelet counts during pregnancy","volume":"379","author":"Reese","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103956_bb0290","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2017-05-781971","article-title":"Thrombocytopenia in pregnancy","volume":"130","author":"Cines","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103956_bb0295","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.23204","article-title":"Gestational thrombocytopenia: a review on recent updates","author":"Habas","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.autrev.2025.103956_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102913","article-title":"Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"21","author":"Bernardoff","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103956_bb0305","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1159\/000516295","article-title":"Cold agglutinin-mediated autoimmune hemolytic anemia in association with antiphospholipid syndrome","volume":"144","author":"Gelman","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.autrev.2025.103956_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101015","article-title":"Hematological manifestations of antiphospholipid syndrome: going beyond thrombosis","volume":"58","author":"El Hasbani","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.autrev.2025.103956_bb0315","article-title":"Thrombosis in antiphospholipid syndrome: current perspectives and challenges in laboratory testing for antiphospholipid antibodies","author":"Devreese","year":"2024","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.autrev.2025.103956_bb0320","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtha.2024.10.022","article-title":"An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"23","author":"Devreese","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103956_bb0325","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/jth.14633","article-title":"The (non-)sense of detecting anti-cardiolipin and anti-\u03b22glycoprotein I IgM antibodies in the antiphospholipid syndrome","volume":"18","author":"Chayoua","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103956_bb0330","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1055\/s-0039-1679901","article-title":"Detection of anti-cardiolipin and anti-\u03b22glycoprotein I antibodies differs between platforms without influence on association with clinical symptoms","volume":"119","author":"Chayoua","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103956_bb0335","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jth.14261","article-title":"Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-\u03b22glycoprotein I antibody detection assays","volume":"16","author":"Chayoua","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103956_bb0340","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103956_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103208","article-title":"Persistence of antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: a longitudinal study from a single centre","volume":"21","author":"Barilaro","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103956_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102395","article-title":"Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis","volume":"18","author":"Chock","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103956_bb0355","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/rheumatology\/kez419","article-title":"Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry","volume":"59","author":"Alijotas-Reig","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103956_bb0360","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the global anti-phospholipid syndrome score","volume":"52","author":"Sciascia","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103956_bb0365","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/art.33340","article-title":"Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events","volume":"64","author":"Otomo","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103956_bb0370","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/keaa203","article-title":"EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies","volume":"60","author":"Pregnolato","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103956_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70122","article-title":"IgG and IgM anti-phosphatidylserine\/prothrombin complex antibody detection may improve classification accuracy of systemic lupus erythematosus and antiphospholipid antibody syndrome","volume":"7","author":"Donath","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2025.103956_bb0380","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/ajcp\/aqy003","article-title":"Performance evaluation and clinical associations of immunoassays that detect antibodies to negatively charged phospholipids other than cardiolipin","volume":"149","author":"Castanon","year":"2018","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.autrev.2025.103956_bb0385","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/jth.15785","article-title":"Added value of antiphosphatidylserine\/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"20","author":"Vandevelde","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103956_bb0390","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.jtha.2023.04.001","article-title":"Added value of antiphosphatidylserine\/prothrombin antibodies in the workup of obstetric antiphospholipid syndrome: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"21","author":"Vandevelde","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103956_bb0395","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ijlh.14268","article-title":"Noncriteria antiphospholipid antibodies in antiphospholipid syndrome","volume":"46","author":"Devreese","year":"2024","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.autrev.2025.103956_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.117761","article-title":"Anti-phosphatidyl-serine\/prothrombin (aPS\/PT) antibodies are superior predictors of LAC presence and APS diagnoses: A single center study","volume":"554","author":"Saadalla","year":"2024","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"10.1016\/j.autrev.2025.103956_bb0405","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.thromres.2018.12.023","article-title":"Prevalence and associations of anti-phosphatidylserine\/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome: aPS\/PT antibodies in primary antiphospholipid syndrome","volume":"174","author":"N\u00fa\u00f1ez-\u00c1lvarez","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2025.103956_bb0410","doi-asserted-by":"crossref","DOI":"10.1093\/mr\/roaf060","article-title":"The clinical significance of non-criteria antiphospholipid antibodies in atypical antiphospholipid syndrome","author":"Xiong","year":"2025","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2025.103956_bb0415","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13621","article-title":"Antiphosphatidylserine\/prothrombin antibodies (aPS\/PT) and risk of obstetric anti-phospholipid syndrome","volume":"89","author":"Zhang","year":"2023","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.autrev.2025.103956_bb0420","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2022.04.021","article-title":"Prevalence of aPhosphatidylserine\/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis","volume":"214","author":"Zhu","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2025.103956_bb0425","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11926-017-0674-4","article-title":"How to identify high-risk APS patients: clinical utility and predictive values of validated scores","volume":"19","author":"Oku","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2025.103956_bb0430","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jth.15585","article-title":"Semiquantitative interpretation of anticardiolipin and anti\u03b22glycoprotein I antibodies measured with various analytical platforms: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"20","author":"Vandevelde","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.autrev.2025.103956_bib531","doi-asserted-by":"crossref","first-page":"102967","DOI":"10.1016\/j.rpth.2025.102967","article-title":"The absence of standardization in antiphospholipid antibody testing may favor the use of 99th percentile cutoffs in antiphospholipid syndrome classification","volume":"9","author":"Anunciaci\u00f3n-Llunell","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"10.1016\/j.autrev.2025.103956_bib532","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2023-225042","article-title":"Correspondence on \u20192023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"83","author":"Miro-Mur","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103956_bb0435","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/rth2.12207","article-title":"Influence of anticardiolipin and anti-\u03b22 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification","volume":"3","author":"Vanoverschelde","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103956_bb0440","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jtha.2024.04.016","volume":"22","author":"Vandevelde","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103956_bb0445","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/CIRCULATIONAHA.111.028522","article-title":"Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies","volume":"124","author":"Zuily","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2025.103956_bb0450","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1177\/09612033221126852","article-title":"Risk of livedo with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis","volume":"31","author":"Loiseau","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2025.103956_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103158","article-title":"Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis","volume":"21","author":"Domingues","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103956_bb0460","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/acr.23317","article-title":"Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration","volume":"70","author":"Tedeschi","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103956_bb0465","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.autrev.2018.12.006","article-title":"The European Registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 1000 consecutive cases","volume":"18","author":"Alijotas-Reig","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103956_bb0470","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3390\/diagnostics14192162","article-title":"Impact of the 2023 ACR\/EULAR classification criteria in women with primary antiphospholipid syndrome during pregnancy","volume":"14","author":"Mart\u00ednez-Taboada","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.autrev.2025.103956_bb0475","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.3390\/jcm13247698","article-title":"Prevalence of antiphospholipid antibody syndrome among patients with recurrent pregnancy loss: impact of the revised 2023 ACR\/EULAR antiphospholipid syndrome criteria","volume":"13","author":"Mercier","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2025.103956_bb0480","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/rheumatology\/keae058","article-title":"2023 ACR\/EULAR classification criteria in existing research cohorts: an international study","volume":"63","author":"Foddai","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103956_bb0485","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ijlh.14416","article-title":"Impact of the 2023 ACR \/ EULAR classification criteria on START2 antiphospholipid registry","volume":"47","author":"Aiello","year":"2025","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.autrev.2025.103956_bb0490","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15175","article-title":"Assessment and comparison of the 2023 ACR\/EULAR APS criteria with the revised Sapporo criteria","volume":"27","author":"Vasi","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103956_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103237","article-title":"Assessment of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria in a Chinese cohort: Impact on clinical practice","volume":"146","author":"Yang","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103956_bb0500","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3390\/diagnostics14192205","article-title":"The validation of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria in a cohort from Turkey","volume":"14","author":"M\u0131s\u0131rc\u0131","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.autrev.2025.103956_bb0505","article-title":"Insights into the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria: findings from a cohort of 205 patients with primary APS","author":"Zen","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103956_bb0510","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3390\/jcm14082826","article-title":"Impact of the 2023 ACR\/EULAR antiphospholipid syndrome criteria on retinal vein occlusion patients","volume":"14","author":"G\u00e1lvez-S\u00e1nchez","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2025.103956_bb0515","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/09612033241301173","article-title":"Real world application of the 2023 ACR\/EULAR antiphospholipid antibody syndrome classification criteria in a pharmacist directed anticoagulation clinic","volume":"34","author":"DeFazio","year":"2025","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2025.103956_bb0520","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3389\/fneur.2018.01001","article-title":"Antiphospholipid syndrome and the neurologist: from pathogenesis to therapy","volume":"9","author":"Fleetwood","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2025.103956_bb0525","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11910-021-01124-z","article-title":"Neurologic manifestations of the antiphospholipid syndrome - an update","volume":"21","author":"Leal Rato","year":"2021","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"21","key":"10.1016\/j.autrev.2025.103956_bib533","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and Management of the Antiphospholipid Syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103956_bib534","doi-asserted-by":"crossref","first-page":"109804","DOI":"10.1016\/j.clim.2023.109804","article-title":"Beyond the classics: The emerging value of anti-phosphatidylserine\/prothrombin antibodies in antiphospholipid syndrome","volume":"256","author":"Ding","year":"2023","journal-title":"Clin Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225002174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225002174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:01:11Z","timestamp":1771513271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225002174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1568997225002174"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103956","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are the 2023 ACR\/EULAR classification criteria a step forward in the management of antiphospholipid syndrome? A literature-based and clinical practice appraisal","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103956"}}